Subcutaneous drug delivery, giventhe use of tailored formulation development solutions, has brought about aparadigm shift in at-home healthcare, enabling users to administer(life-saving) medications without having to rely on medical professionals
Roots Analysis is pleased to announce the publication of its recent study,titled “Subcutaneous Biologics,Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to itslist of offerings.
Thereport provides a detailed study on the current market landscape and futurepotential of biologics designed for subcutaneous administration. In addition,the study provides an in-depth analysis of the formulation technologies anddrug delivery systems (focusing on large volume wearable injectors,autoinjectors, pen injectors, needle-free injectors, drug reconstitutionsystems, prefilled syringes and implants) that enable subcutaneous delivery ofthe biologic drugs. Amongst other elements, the report features the following:
§ A detailed assessment of the current market landscape ofcommercially available and clinical-stage biologics that are designed fordelivery via the subcutaneous route
§ Acase study on leading subcutaneous biologics (in terms of revenues generated),featuring details on mechanism of action, development history, annual sales,technology platform (if available), and a comparison of their intravenous andsubcutaneous formulations (if applicable).
§ Anassessment of the various subcutaneous formulation technologies along withinformation on developers, type of pharmacological molecule, route ofadministration, mechanisms of action and primary advantage(s).
§ Aninsightful three-dimensional comparison of the subcutaneous formulationtechnology developers, based on pipeline strength, supplier power of thedeveloper and primary advantages offered by their respective technologies.
§ Elaborateprofiles of key technology developers, featuring a brief overview of thecompany, its technology portfolio, product portfolio, financial information (ifavailable), recent developments and an informed future outlook.
§ Ananalysis of collaborations andpartnership agreements inked by the subcutaneous formulation technologydevelopers since 2011
§ Anin-depth review of the most advanced and popular subcutaneous drug deliverysystems, including large volume wearable injectors, autoinjectors, peninjectors, needle-free injectors, drug reconstitution systems, prefilledsyringes and implants
§ Acomprehensive product competitiveness analysis of subcutaneous large volumewearable injectors, subcutaneous autoinjectors, subcutaneous needle-freeinjectors and pre-filled syringes
§ Adiscussion on affiliated trends, key drivers and challenges, which are likelyto impact the industry's evolution, under a comprehensive SWOT framework
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow):
§ Phaseof development
§ Approved
§ Pre-registration & Phase III
§ Phase II & Phase II/III
§ Typeof molecule
§ Cell and gene therapies
§ Monoclonal antibodies
§ Proteins
§ Peptides (recombinant)
§ Vaccines
§ Others
§ Targettherapeutic area
§ Autoimmune disorders
§ Blood disorders
§ Bone disorders
§ Genetic disorders
§ Metabolic disorders
§ Neurological disorders
§ Oncological disorders
§ Respiratory disorders
§ Others
§ Typeof drug delivery system
§ Large volume wearable injectors
§ Autoinjectors
§ Prefilled syringes
§ Needle-free injectors
§ Drug reconstitution systems
§ Revenuesfrom licensing deals
§ Upfront payments
§ Milestone payments
§ Keygeographical regions
§ North America
§ Europe
§ Asia Pacific
§ Rest of the World
§ Transcripts of interviews held with the following seniorlevel representatives of stakeholder companies
§ Deborah Bitterfield (Founder and Chief Executive Officer, Lindy Biosciences)
§ Matthew Young (Founder and Chief Technology Officer, Oval MedicalTechnologies)
§ Steve Prestrelski (Founder and Chief Scientific Officer, XerisPharmaceuticals), Hong Qi (Vice President, Product Development, XerisPharmaceuticals) and Scott Coleman (Senior Scientist, Formulation, XerisPharmaceuticals)
§ David Daily (Co-Founder and Chief Executive Officer, DALI Medical Devices)
§ Michael Reilly (Co-Founder and Chief Executive Officer andCo-Founder, ExcelseBio)
§ Poonam R Velagaleti (Co-Founder, i-novion)
§ Michael Hooven (Chief Executive Officer, Enable Injections)
§ Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
§ Patrick Anquetil (Chief Executive Officer, PortalInstruments)
§ Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
§ Tiffany H. Burke (Director, Global Communications, WestPharmaceutical Services) and Graham Reynolds (VicePresident and General Manager, Global Biologics, WestPharmaceutical Services)
§ David Heuzé (Communication Leader, MedinCell)
Keycompanies covered in the report
§ Adocia
§ AjinomotoBio-Pharma Services
§ Arecor
§ Alteogen
§ AscendisPharma
§ AvadelPharmaceuticals
§ Camurus
§ CreativeBioMart
§ CreativeBiolabs
§ DURECT
§ EaglePharmaceuticals
§ HalozymeTherapeutics
§ MedinCell
§ XerisPharmaceuticals
§ SerinaTherapeutics
For additionaldetails, please visit
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
1. Global AutoinjectorsMarket(3rd Edition), 2020-2030
2. Prefilled SyringesMarket(5th Edition), 2020-2030
3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and OtherMechanisms) Market, 2019-2030
4. Large Volume Wearable Injectors Market (4th Edition), 2018-2030
About Roots Analysis
Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
